You are currently browsing the archives for 1 July 2017.
Displaying 1 entry.

Boehringer Ingelheim awards milestone payment to Xencor Xencor.

The quantity of the milestone payment had not been disclosed.D., CEO of Xencor. ‘Our XmAb technology can be fueling Xencor’s inner pipeline, which includes many optimized antibodies for both oncology and autoimmune illnesses.’ Within its license contract, Boehringer Ingelheim in addition has exercised an choice to utilize XmAb Great ADCC technology for another discovery system in oncology against an undisclosed focus on.. Boehringer Ingelheim awards milestone payment to Xencor Xencor, Inc. Announced today that the business received a milestone payment from Boehringer Ingelheim.